ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biologic response modifiers"

  • Abstract Number: 1898 • ACR Convergence 2020

    Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis

    Loïc Choquette Sauvageau1, Denis Choquette2, Louis Bessette3, Isabelle Ferdinand1, Boulos Haraoui4, Frédéric Massicotte1, Jean-Pierre Pelletier2, Jean-Pierre Raynauld2, Marie-Anaïs Rémillard1, Diane Sauvageau1, Édith Villeneuve1 and Louis Coupal1, 1Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 2Institut de Rhumatologie de Montréal, Montreal, Canada, 3Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, 4Rheumatology Institute of Montréal, Montreal, Canada

    Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing.…
  • Abstract Number: 2005 • ACR Convergence 2020

    Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis

    Felice Rivellese1, Frances Humby2, Giovanni Giorli2, Alessandra Nerviani1, Rebecca Hands2, Liliane Fossati-Jimack2, Georgina Thorborn2, Myles Lewis1 and Costantino Pitzalis2, 1Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, 2Queen Mary University of London, London, United Kingdom

    Background/Purpose: The results of the R4RA trial, the first biopsy-based RCT in TNF-i inadequate responders patients with Rheumatoid Arthritis (RA), showed that molecular stratification of…
  • Abstract Number: 2032 • ACR Convergence 2020

    Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis

    Valeria Rios Rodriguez1, Mikhail Protopopov1, Fabian Proft1, Judith Rademacher1, Burkhard Muche1, Anne-Katrin Weber1, Susanne Lüders1, Hildrun Haibel1, Maryna Verba1, Joachim Sieper1 and Denis Poddubnyy2, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: There is few data available regarding differences in body composition and its possible changes in patients with ankylosing spondylitis (AS) treated with biological disease-modifying…
  • Abstract Number: 0227 • ACR Convergence 2020

    Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors

    Lucía Vega-Álvarez1, Itziar Calvo-Zorrilla1, Oihane Ibarguengoitia-Barrena1, Juan M. Blanco-Madrigal1, David Montero-Seisdedos2, Carmen L. Garcia-Gomez1, Maria Esther Ruiz-Lucea1, Ana R. Inchaurbe-Pellejero1, Ignacio Torre-Salaberri1, Clara E. Perez-Velasquez1, Olaia Fernandez-Berrizbeitia1, Eduardo Cuende-Quintana3, Iñigo R. Gorostiza-Hormaetxe4, María Luz García-Vivar1 and Eva Galindez-Agirregoikoa1, 1Basurto University Hospital, BILBAO, Spain, 2Basurto University Hospital, Bilbao, Pais Vasco, Spain, 3Basurto University Hospital, Madrid, Spain, 4Basurto University Hospital, Bilbao

    Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
  • Abstract Number: 0333 • ACR Convergence 2020

    Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis

    Denis Choquette1, Loïc Choquette Sauvageau2, Louis Bessette3, Isabelle Ferdinand2, Boulos Haraoui4, Frédéric Massicotte2, Jean-Pierre Pelletier1, Jean-Pierre Raynauld1, Marie-Anaïs Rémillard2, Diane Sauvageau2, Édith Villeneuve2 and Louis Coupal2, 1Institut de Rhumatologie de Montréal, Montreal, Canada, 2Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 3Laval University, Quebec, Canada, 4Rheumatology Institute of Montréal, Montreal, Canada

    Background/Purpose: The treatment of psoriatic arthritis has evolved with the addition of agents targeting a different cytokine, Il-17 introduced in 2016. It has proven to…
  • Abstract Number: 0592 • ACR Convergence 2020

    A Rheumatology-Driven Protocol and Treatment Algorithm of SARS-CoV-2 Cytokine Release Syndrome and Its Associated Outcomes

    Sandy Lee1, Neha Chiruvolu2, Muntarin Karim3, Patil Injean4, Loomee Doo5, Donna Jose6, Deepa Panikkath1, Micah Yu5, Anna Lafian5, Wendy De La Pena7, Albert Chow8, Karina Torralba9, Vaneet Sandhu10, Mehrnaz Hojjati5, Marven Cabling5 and Christina Downey1, 1Loma Linda University Medical Center, Redlands, CA, 2UC Riverside School of Medicine, Riverside, CA, 3Loma Linda University Health System, Loma Linda, CA, 4LOMA LINDA UNIVERSITY MEDICAL CENTER - RHEUMATOLOGY, Redlands, CA, 5Loma Linda University Medical Center, LOMA LINDA, CA, 6Loma Linda University Medical Center, Ontario, CA, 7PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Loma Linda University, San Bernardino, CA, 9Loma Linda University School of Medicine, Redlands, CA, 10Loma Linda University, Loma Linda, CA

    Background/Purpose: The newly identified SARS-CoV-2 has brought Cytokine Release Syndrome (CRS) to a level of prominence not often seen in adult medicine. Mortality rates of…
  • Abstract Number: 0623 • ACR Convergence 2020

    Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort

    Neha Chiruvolu1, Muntarin Karim2, Patil Injean3, Sandy Lee3, Karina Torralba4, Christina Downey3, Mehrnaz Hojjati5, Loomee Doo5, Donna Jose6, Deepa Panikkath3, Micah Yu5, Anna Lafian5, Marven Cabling5 and Vaneet Sandhu7, 1UC Riverside School of Medicine, Riverside, CA, 2Loma Linda University Health System, Loma Linda, CA, 3Loma Linda University Medical Center, Redlands, CA, 4Loma Linda University School of Medicine, Redlands, CA, 5Loma Linda University Medical Center, Loma Linda, CA, 6Loma Linda University Medical Center, Ontario, CA, 7Loma Linda University, Loma Linda, CA

    Background/Purpose: Cytokine Release Syndrome (CRS) or Macrophage Activation Syndrome (MAS) is a life threating hyperinflammatory condition that can complicate rheumatic disease as well as infections…
  • Abstract Number: 0712 • ACR Convergence 2020

    Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis

    Ilaria Maccora1, Gabriele Simonini2, Alessandra Bettiol3, Ilaria Pagnini4, Niccolò Lombardi5, Valerio Maniscalco6, Giada Crescioli5, Edoardo Marrani7, Roberto Bonaiuti5, Maria Vincenza Mastrolia8, Claudia Ravaldi9 and Alfredo Vannacci5, 1Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, 2Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, 32. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, 41. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, 52. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, 61. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, 7University of Florence, Firenze, Italy, 8Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, 93. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy

    Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
  • Abstract Number: 0719 • ACR Convergence 2020

    Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study

    Edoardo Marrani1, Hendrik Rusche2, Francesco Terzani3, Elisa Peroni4, Feliciana Real-Fernandez5, Olivier Monasson4, Roberta Ponti6, Gabriele Simonini7, Anna Maria Papini3 and Paolo Rovero5, 1University of Florence, Firenze, Italy, 2Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise,, France, 3PeptLab, Dep. Chemistry, University of Florence, Sesto FIorentino, Italy, 4Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, cergy-pontoise, France, 5PeptLab, Dep. NEUROFARBA, University of Florence, Firenze, Italy, 6Pediatric Department, University of Udine, udine, Italy, 7Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy

    Background/Purpose: Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported…
  • Abstract Number: 0833 • ACR Convergence 2020

    Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics

    Andrea De Diego Sola1, César Antonio Egües Dubuc2, Nerea Alcorta Lorenzo1, Jesús Alejandro Valero Jaimes2, Olga Maíz Alonso3, Luis Maria Lopez Dominguez1, Esther Uriarte Isacelaya4, Jorge Cancio Fanlo5, María Asunción Aranguren Redondo6, María Belén Irastorza Larburu7 and Joaquín María Belzunegui Otano3, 1Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Pais Vasco, Spain, 2Hospital Universitario Donostia, San Sebastián, Spain, 3Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 4Hospital Universitario Donostia, San Sebastian, Spain, 5Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 6Pharmacology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 7Pharmacology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastián, Spain

    Background/Purpose: The emergence of biological disease modifying drugs (bDMARD) has allowed a targeted approach to rheumatoid arthritis (RA) ("treat-to-treat" strategy).  Once sustained remission is achieved,…
  • Abstract Number: 0901 • ACR Convergence 2020

    Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence

    Robert Moots1, Andy Cross2, Helen Wright2, Steven Edwards2, Nicola Goodson3, Jenny Hawkes3, Ayren Mediana1 and Helen Frankland1, 1Liverpool University Hospitals, Liverpool, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom, 3University of Liverpool, Liverpool

    Background/Purpose: Secukinumab is a monoclonal antibody that neutralises IL-17A, which plays a key role in the IL-23/17A axis underlying the pathophysiology of psoriatic arthritis (PsA). …
  • Abstract Number: 1014 • ACR Convergence 2020

    Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years

    John Hanly1 and Lynn Lethbridge2, 1Dalhousie University, Halifax, NS, Canada, 2Dalhousie University, Halifax, Canada

    Background/Purpose: The objective of the current study was to examine the change in prescribing patterns for older adults with RA over a 20 year period…
  • Abstract Number: 050 • 2020 Pediatric Rheumatology Symposium

    Long Term Safety of Biologics and Biosimilars in Pediatric Rheumatic Diseases: An Experience from a Single North Indian Centre

    MANJARI AGARWAL 1, Sujata Sawhney2 and Anju Singh 3, 1Sir Ganga Ram Hospital, NEW DELHI, Delhi, India, 2Sir ganga ram hospital, Sector 37 noida, Uttar Pradesh, India, 3Sir Ganga Ram Hospital, delhi, India

    Background/Purpose:  The use of biologic response modifiers(BRMs) is associated with an increased risk of infections.We also use biosimilars for two reasons:1. originator not available, like…
  • Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting

    Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards

    Shubha Kollampare1, C. Kent Kwoh1,2, Wei-Hsuan Lo-Ciganic3, Lili Zhou2,4, Erin L. Ashbeck2 and Dominick Sudano1, 1Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, 2University of Arizona Arthritis Center, Tucson, AZ, 3Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, 4College of Pharmacy, University of Arizona, Tucson, AZ

    Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…
  • Abstract Number: 206 • 2017 ACR/ARHP Annual Meeting

    Real World IGRA Testing in Rheumatology Practice

    Paul DeMarco1,2, Megan Bishop3, Ashling Smith4, Herbert S. B. Baraf1,5, Andrew Gregory DeMarco6, Temitope Ademola7, Deborah Contreras8, Adalisa Enriquez RMA1, Lisa Klein1, Kayra Perez1, Sandra Ventura1, Janice Whyte-Whitworth1, Vince Calhoun1, Theresa Bass Goldman1 and Alan K Matsumoto1,9, 1The Center for Rheumatology and Bone Research, Wheaton, MD, 2Division of Rheumatology, Department of Medicine, Georgetown University School of Medicine, Washington, DC, 3Clinical Trials, The Center for Rheumatology and Bone Research, Wheaton, MD, 42730 University Blvd West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, 5Department of Medicine, George Washington University School of Medicine, Washington, DC, 6Department of Biochemistry and Molecular Cellular Biology, Georgetown University Department of Biochemistry and Molecular Cellular Biology, Washington, DC, 7The Center for Rheumatology and Bone Research, Washington, DC, 82730 University Boulevard West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, 9Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD

    Background/Purpose: Mycobacterium tuberculosis (MTb) screening is routine for clinical trial protocols, & authorization for immunomodulators use by health insurances. Real world data is needed to…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology